Menu
Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 14
Pharmacogenomics and Personalized Medicine
- View all (329)
- Volume 14, 2021 (42)
- Volume 13, 2020 (72)
- Volume 12, 2019 (34)
- Volume 11, 2018 (24)
- Volume 10, 2017 (31)
- Volume 9, 2016 (14)
- Volume 8, 2015 (16)
- Volume 7, 2014 (37)
- Volume 6, 2013 (15)
- Volume 5, 2012 (12)
- Volume 4, 2011 (10)
- Volume 3, 2010 (11)
- Volume 2, 2009 (9)
- Volume 1, 2008 (2)
Archive: Volume 14, 2021
DNA Methylation of Fluoxetine Response in Child and Adolescence: Preliminary Results
Martinez-Pinteño A, Rodriguez N, Blázquez A, Plana MT, Varela E, Gassó P, Lafuente A, Lazaro L, Mas S
Pharmacogenomics and Personalized Medicine 2021, 14:459-467
Published Date: 19 April 2021
CSF1R is a Prognostic Biomarker and Correlated with Immune Cell Infiltration in the Gastric Cancer Microenvironment
Chen D, Xiong L, Zhang L, Yu H, Xu Y, Wang M, Jiang X, Xiong Z
Pharmacogenomics and Personalized Medicine 2021, 14:445-457
Published Date: 13 April 2021
Assessment of Weighted Gene Co-Expression Network Analysis to Explore Key Pathways and Novel Biomarkers in Muscular Dystrophy
Xu X, Hao Y, Wu J, Zhao J, Xiong S
Pharmacogenomics and Personalized Medicine 2021, 14:431-444
Published Date: 13 April 2021
CYP2C9*3/*3 Gene Expression Affects the Total and Free Concentrations of Valproic Acid in Pediatric Patients with Epilepsy
Wu X, Dong W, Li H, Yang X, Jin Y, Zhang Z, Jiang Y
Pharmacogenomics and Personalized Medicine 2021, 14:417-430
Published Date: 9 April 2021
Non-Classical 21-Hydroxylase Deficiency: Analysis of a Mutant Gene in a Uyghur Family and Literature Review
Maimaitiming J, Amuti G, TuHuTi A, Chen Y, Song XX, Wang J, Alimu A, Zhang K, Abudounaiyimu M, Jiang J, Wang XL, Guo YY
Pharmacogenomics and Personalized Medicine 2021, 14:409-416
Published Date: 7 April 2021
CHN1 is a Novel Prognostic Marker for Diffuse Large B-Cell Lymphoma
Sun J, Zhu X, Zhao Y, Zhou Q, Qi R, Liu H
Pharmacogenomics and Personalized Medicine 2021, 14:397-408
Published Date: 1 April 2021
Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana [Corrigendum]
Maseng MJ, Tawe L, Thami PK, Seatla KK, Moyo S, Martinelli A, Kasvosve I, Novitsky V, Essex M, Russo G, Gaseitsiwe S, Paganotti GM
Pharmacogenomics and Personalized Medicine 2021, 14:395-396
Published Date: 31 March 2021
Correlation Study on HLA-DR and CD117 (c-Kit) Expressions: Its Prognosis and Treatment Response in Acute Myeloid Leukemia Patients
El-Meligui YM, Abd Elrhman HE, Salahuddin A, Hamouda MA, Kassem AB
Pharmacogenomics and Personalized Medicine 2021, 14:381-393
Published Date: 30 March 2021
Pathway to Ascertain the Role of Pharmacogenomics in Healthcare Utilization Outcomes [Letter]
Roman YM
Pharmacogenomics and Personalized Medicine 2021, 14:379-380
Published Date: 26 March 2021
Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen
Zhu X, Zhu J, Sun F, Zhen Z, Zhou D, Lu S, Huang J, Que Y, Zhang L, Cai R, Wang J, Zhang Y
Pharmacogenomics and Personalized Medicine 2021, 14:369-377
Published Date: 23 March 2021
The Association of Single-Nucleotide Polymorphism rs13181 in ERCC2 with Risk and Prognosis of Nasopharyngeal Carcinoma in an Endemic Chinese Population
Wei Z, Yao M, Ning S, Wu Y, Zhou X, Zhong C, Yan K, Xie Y
Pharmacogenomics and Personalized Medicine 2021, 14:359-367
Published Date: 17 March 2021
Skeletal Abnormalities and VDR1 Gene Polymorphisms in Mucopolysaccharidosis Patients
Alkhzouz C, Cabau G, Lazea C, Asavoaie C, Bucerzan S, Mirea AM, Farcas M, Miclaus M Jnr, Popp R, Miclea D
Pharmacogenomics and Personalized Medicine 2021, 14:349-358
Published Date: 17 March 2021
Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana
Maseng MJ, Tawe L, Thami PK, Seatla KK, Moyo S, Martinelli A, Kasvosve I, Novitsky V, Essex M, Russo G, Gaseitsiwe S, Paganotti GM
Pharmacogenomics and Personalized Medicine 2021, 14:335-347
Published Date: 16 March 2021
Challenges Involved in Incorporating Personalised Treatment Plan as Routine Care of Patients with Diabetes
Unnikrishnan R, Radha V, Mohan V
Pharmacogenomics and Personalized Medicine 2021, 14:327-333
Published Date: 16 March 2021
Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus
Pasternak AL, Marshall VD, Gersch CL, Rae JM, Englesbe M, Park JM
Pharmacogenomics and Personalized Medicine 2021, 14:319-326
Published Date: 12 March 2021
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
Pacini L, Jenks AD, Vyse S, Wilding CP, Arthur A, Huang PH
Pharmacogenomics and Personalized Medicine 2021, 14:301-317
Published Date: 9 March 2021
Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype
Fonseca DJ, Morel A, Llinás-Caballero K, Bolívar-Salazar D, Laissue P
Pharmacogenomics and Personalized Medicine 2021, 14:287-299
Published Date: 1 March 2021
Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions
Jeiziner C, Stäuble CK, Lampert ML, Hersberger KE, Meyer zu Schwabedissen HE
Pharmacogenomics and Personalized Medicine 2021, 14:279-286
Published Date: 19 February 2021
TSC2 Mutations Were Associated with the Early Recurrence of Patients with HCC Underwent Hepatectomy
Song K, He F, Xin Y, Guan G, Huo J, Zhu Q, Fan N, Guo Y, Zang Y, Wu L
Pharmacogenomics and Personalized Medicine 2021, 14:269-278
Published Date: 16 February 2021
Optimization of Busulfan Dosing Regimen in Pediatric Patients Using a Population Pharmacokinetic Model Incorporating GST Mutations
Yuan J, Sun N, Feng X, He H, Mei D, Zhu G, Zhao L
Pharmacogenomics and Personalized Medicine 2021, 14:253-268
Published Date: 15 February 2021
Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort
Machado-Rugolo J, Gutierrez Prieto T, Fabro AT, Parra Cuentas ER, Sá VK, Baldavira CM, Rainho CA, Castelli EC, Farhat C, Takagaki TY, Nagai MA, Capelozzi VL
Pharmacogenomics and Personalized Medicine 2021, 14:239-252
Published Date: 15 February 2021
No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study
Takahashi PY, Ryu E, Bielinski SJ, Hathcock M, Jenkins GD, Cerhan JR, Olson JE
Pharmacogenomics and Personalized Medicine 2021, 14:229-237
Published Date: 11 February 2021
Correlations Between TIMD-4 Gene Variants and the Risk and Clinical Features of Rheumatoid Arthritis in a Chinese Population
Yang Z, Liu S, Zhou L, Zhang H, Xu N
Pharmacogenomics and Personalized Medicine 2021, 14:221-228
Published Date: 9 February 2021
Identification of Crucial Genes and Pathways Associated with Atherosclerotic Plaque in Diabetic Patients
Li YY, Zhang S, Wang H, Zhang SX, Xu T, Chen SW, Zhang Y, Chen Y
Pharmacogenomics and Personalized Medicine 2021, 14:211-220
Published Date: 4 February 2021
TPMT Genetic Variability and Its Association with Hematotoxicity in Indonesian Children with Acute Lymphoblastic Leukemia in Maintenance Therapy
Rosdiana DS, Setiabudy R, Andalusia R, Gatot D, Louisa M, Bardosono S, Instiaty I
Pharmacogenomics and Personalized Medicine 2021, 14:199-210
Published Date: 3 February 2021
Association of CYP3A5 Gene Polymorphisms and Amlodipine-Induced Peripheral Edema in Chinese Han Patients with Essential Hypertension
Liang H, Zhang X, Ma Z, Sun Y, Shu C, Zhu Y, Zhang Y, Hu S, Fu X, Liu L
Pharmacogenomics and Personalized Medicine 2021, 14:189-197
Published Date: 2 February 2021
The Association Between Azathioprine Genetic Polymorphisms, Clinical Efficacy and Adverse Drug Reactions Among Egyptian Patients with Autoimmune Diseases
Abuelsoud N, Fayed H, Elkateeb E
Pharmacogenomics and Personalized Medicine 2021, 14:179-187
Published Date: 2 February 2021
Assessment of the Role of Selected SMAD3 and SMAD4 Genes Polymorphisms in the Development of Colorectal Cancer: Preliminary Research
Wosiak A, Wodziński D, Michalska K, Pietrzak J, Kordek R, Balcerczak E
Pharmacogenomics and Personalized Medicine 2021, 14:167-178
Published Date: 29 January 2021
Relationship Between Interleukin-6 −174G/C Genetic Variant and Efficacy of Methotrexate Treatment in Psoriatic Arthritis Patients
Sokolik R, Iwaszko M, Świerkot J, Wysoczańska B, Korman L, Wiland P, Bogunia-Kubik K
Pharmacogenomics and Personalized Medicine 2021, 14:157-166
Published Date: 28 January 2021
Genetic Polymorphism Effect on Warfarin–Rifampin Interaction: A Case Report and Review of Literature
Salem M, Eljilany I, El-Bardissy A, Elewa H
Pharmacogenomics and Personalized Medicine 2021, 14:149-156
Published Date: 26 January 2021
CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
Nizamuddin S, Dubey S, Singh S, Sharma S, Machha P, Thangaraj K
Pharmacogenomics and Personalized Medicine 2021, 14:135-147
Published Date: 27 January 2021
Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon
Fernandes MR, Rodrigues JCG, Maroñas O, Latorre-Pellicer A, Cruz R, Guerreiro JF, Burbano RMR, Assumpção PP, Ribeiro-dos-Santos A, Santos SEB, Carracedo A, Santos NPC
Pharmacogenomics and Personalized Medicine 2021, 14:117-133
Published Date: 22 January 2021
No Association Between FTO Gene Polymorphisms and Central Nervous System Tumor Susceptibility in Chinese Children
Liao Y, Yuan L, Zhang Z, Lin A, Zhou J, Zhuo Z, Zhao J
Pharmacogenomics and Personalized Medicine 2021, 14:109-115
Published Date: 19 January 2021
STAT6 rs324015 Gene Polymorphism Increases Ulcerative Colitis Risk: A Case–Control Study
Dai L, Zhang D, Qian Y, Wan Y, Chang S, Qian H
Pharmacogenomics and Personalized Medicine 2021, 14:101-107
Published Date: 19 January 2021
High LARGE1 Expression May Predict Benefit from Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer
Liu Y, Huang S, Kuang M, Wang H, Xie Q
Pharmacogenomics and Personalized Medicine 2021, 14:87-99
Published Date: 18 January 2021
Genetic Interaction of H19 and TGFBR1 Polymorphisms with Risk of Epilepsy in a Chinese Population
Zheng Z, Yan Y, Guo Q, Wang L, Han X, Liu S
Pharmacogenomics and Personalized Medicine 2021, 14:77-86
Published Date: 14 January 2021
Review on Databases and Bioinformatic Approaches on Pharmacogenomics of Adverse Drug Reactions
Tong H, Phan NVT, Nguyen TT, Nguyen DV, Vo NS, Le L
Pharmacogenomics and Personalized Medicine 2021, 14:61-75
Published Date: 13 January 2021
Genetic Variants of the MIF Gene and Susceptibility of Rectal Cancer
Chuo D, Lin D, Yin M, Chen Y
Pharmacogenomics and Personalized Medicine 2021, 14:55-60
Published Date: 12 January 2021
The Prognostic Value of DNA Methylation, Post-Translational Modifications and Correlated with Immune Infiltrates in Gynecologic Cancers
Shang C, Li Y, Wu Z, Han Q, Zhu Y, He T, Guo H
Pharmacogenomics and Personalized Medicine 2021, 14:39-53
Published Date: 12 January 2021
Mitochondrial DNA in Fresh versus Frozen Embryo Culture Media of Polycystic Ovarian Syndrome Patients Undergoing Invitro Fertilization: A Possible Predictive Marker of a Successful Pregnancy
Sayed GA, Al-Sawaf HA, Al-Sawaf AH, Saeid M, Maged A, Ibrahim IH
Pharmacogenomics and Personalized Medicine 2021, 14:27-38
Published Date: 11 January 2021
Identification of Four Genes as Prognosis Signatures in Lung Adenocarcinoma Microenvironment
Yao Y, Zhang T, Qi L, Liu R, Liu G, Li J, Sun C
Pharmacogenomics and Personalized Medicine 2021, 14:15-26
Published Date: 8 January 2021
Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin
Srisawasdi P, Rodcharoen P, Vanavanan S, Chittamma A, Sukasem C, Na nakorn C, Dejthevaporn C, Kroll MH
Pharmacogenomics and Personalized Medicine 2021, 14:1-13
Published Date: 6 January 2021